logo
Plus   Neg
Share
Email

Bank Of Hawaii Corp. Q4 Profit Tops Estimates - Quick Facts

Bank of Hawaii Corp. (BOH) reported fourth-quarter earnings per share of $1.45, an increase from $1.30, a year ago. On average, five analysts polled by Thomson Reuters expected the company to report profit per share of $1.44, for the quarter. Analysts' estimates typically exclude special items.

Fourth-quarter net interest income, on a taxable-equivalent basis, was $124.2 million, a decrease of $1.0 million compared to prior year. Noninterest income was $47.7 million compared to $42.1 million, last year. Noninterest income in the fourth quarter
of 2019 included a gain of $3.8 million related to the early buyout of a leveraged lease that was partially offset by a reduction in mortgage banking income and customer derivative activity. Analysts expected revenue of $170.54 million for the quarter.

Peter Ho, CEO, said: "Our loan balances grew 5.2 percent in 2019 and our deposit balances grew 5.0 percent compared with 2018. Our asset quality, capital and liquidity all remain strong."

The company's Board declared a quarterly cash dividend of $0.67 per share. The dividend will be payable on March 13, 2020 to shareholders of record at the close of business on February 28, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT